Research
Hormonal
GLP-1 receptor agonists have shown remarkable weight loss potential comparable to bariatric interventions.
GLP-1 receptor agonists may be a viable non-invasive alternative for weight loss in some patients.
StrongSupportsmedium confidence
Recently, glucagon-like insulinotropic peptide-1 receptor agonists (GLP) and the GLP-1/gastric inhibitory polypeptide co-agonist–Tirzepatide have shown remarkable weight loss potential, which is at par with bariatric interventions in some patients.
Why this rating
The claim is based on recent findings regarding GLP-1 receptor agonists.
Source
Bariatric and endo-bariatric interventions for diabetes: What is the current evidence?
Sunetra Mondal et al. · World Journal of Diabetes · 2024
DOI 10.4239/wjd.v15.i11.2255
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →